GVK Bio, Wyeth sign drug discovery pact

June 2008
Chemical Business;Jun2008, Vol. 22 Issue 6, p67
Trade Publication
The article reports on an agreement entered into by GVK Bio and Wyeth Pharmaceuticals to conduct drug discovery research and generate intellectual property in India in 2008. GVK Bio will apply in-house capabilities in discovery chemistry and toxicology in order to promote such collaborative research programme. Under the agreement, GVK Bio will obtain initial payments and milestone fees based on the development of the study.


Related Articles

  • WHO, Wyeth partner on phase I drug trial.  // Ophthalmology Times;6/15/2004, Vol. 29 Issue 12, p45 

    Reports on the agreement between Wyeth Pharmaceuticals Inc. and the World Health Organization to proceed with a clinical trial to investigate the safety and efficacy of moxidectin to treat onchocerciasis in Madison, New Jersey. Goal of the effort to develop an oral formula for moxidectin;...

  • Catalyst, Wyeth in $500M Hemophilia Products Deal.  // Bioworld Week;7/6/2009, Vol. 17 Issue 27, p3 

    The article reports on the plan of Catalyst Biosciences Inc. to closed a $500 million deal with Wyeth's pharmaceutical division for the research and development of Factor VIIa products. It states that the products aimed to treat hemophilia and other bleeding conditions. It notes that under the...

  • Morphotek Delivers Cell Line to Wyeth.  // Drug Discovery & Development;Oct2002, Vol. 5 Issue 9, p23 

    Reports on an announcement by Exton, Pennsylvania-based Morphotek Inc. that Madison, New Jersey-based Wyeth Pharmaceuticals Inc. has accepted an evolved cancer cell line from the companies' research collaboration. Result of acceptance of the cell line by the pharmaceutical company; Features of...

  • GVK Bio acquires US research firm.  // FRPT- Chemical Snapshot;2/16/2014, p11 

    The article reports on the acquisition of Aragen Bioscience Inc., a U.S.-based privately-held pre-clinical contract research organisation (CRO), by CRO, GVK Bio, of Hyderabad, India. It mentions that the acquisition will strengthen the expertise of GK Bio to large-molecule research and...

  • Wyeth Cancels Hedgehog Collaboration with Curis. Turner, Tiffany // BioWorld Today;3/11/2008, Vol. 19 Issue 48, p2 

    This article reports on the decision by Wyeth Pharmaceuticals to terminate its collaboration agreement with Curis Inc. in the U.S. in 2008. The agreement focused on the preclinical development of small-molecule and protein Hedgehog agonists for stroke and cardiovascular indications. Shares of...

  • Data Integration Serves a Clinical Trial Need for Speed. Keating, Sean // Drug Discovery & Development;Nov2004, Vol. 7 Issue 11, p61 

    Reports on how different pharmaceutical companies and contract research organizations are managing their global clinical trials. Capability of Wyeth Pharmaceuticals' E-Clinical system to review reports on clinical trials and handle all information associated with a clinical trial; Advantages of...

  • Untitled.  // Drug Discovery & Development;Feb2008, Vol. 11 Issue 2, p37 

    The article presents several research related to drug discovery and development. A study to compare the factors that contribute to DNA mutations is conducted by Kateryna Makova and her colleagues at Penn State. Amgen and Wyeth Pharmaceuticals announced that 12 weeks of ENBREL treatment reduced...

  • OTHER NEWS TO NOTE.  // BioWorld International;3/5/2008, Vol. 13 Issue 10, p2 

    This section offers news briefs on the biotechnology industry as of March 5, 2008. Amarin Corp. PLC has obtained the exclusive development and commercialization rights to a broad intellectual property portfolio in the field of lipid science from Scarista Ltd. BioAlliance Pharma SA reported an...

  • RoviSys lands deal with drug company. Stacklin, Jeff // Crain's Cleveland Business;5/5/2003, Vol. 24 Issue 18, p3 

    Ohio-based RoviSys Co., a provider of software and engineering services for developing automated manufacturing systems, has won a $2 million contract with Collegeville, Pennsylvania-based pharmaceutical company Wyeth Pharmaceuticals Inc., that will help Wyeth's business growth in Aurora,...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics